Abstract
Introduction: In this study, it was aimed to evaluate the relationship
between the use of two different sodium glucose transporter 2 (SGLT2) inhibitors, dapagliflozin and empagliflozin, and renal tubular injury,
with type 2 diabetes mellitus patients obtaining levels of neutrophil gelatinase-associated lipocalin (NGAL) in serum and arylesterase in urine.
Methods: Sixty patients diagnosed type 2 diabetes mellitus were enrolled in
the study; 30 of these patients used dapagliflozin and 30 patients used empagliflozin. The serum NGAL levels of the patients were measured by sandwich
ELISA method while urine arylesterase levels were studied by centrifugation.
Results: No significant relationship was found between the considered
SGLT-2 inhibitors and the occurrence of acute tubular damage. There
was no significant difference in serum NGAL levels or urinary arylesterase levels between the dapagliflozin and empagliflozin groups. The levels of microalbuminuria were significantly decreased in both groups.
Conclusion: It can be said that there is no significant relationship
between SGLT-2 inhibitors and renal tubular damage, with no significant difference found between dapagliflozin and empagliflozin.
Details
| Primary Language | English |
|---|---|
| Subjects | Traditional, Complementary and Integrative Medicine (Other) |
| Journal Section | Research Articles |
| Authors | |
| Publication Date | July 3, 2023 |
| Published in Issue | Year 2023 Volume: 2 Issue: 3 |
